Related Experiment Videos
[Treatment of juvenile diabetes mellitus with continuous subcutaneous insulin infusion (CSII)]
Tijdschrift Voor Kindergeneeskunde
|December 1, 1983
Insights
Continuous subcutaneous insulin infusion (CSII) therapy normalized blood glucose and HbA1c levels in six diabetic children. The insulin pump did not hinder daily activities, suggesting CSII is a beneficial treatment for pediatric diabetes.
Area of Science:
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Diabetes mellitus in children presents unique treatment challenges.
- Effective glycemic control is crucial for preventing long-term complications in pediatric patients.
Purpose of the Study:
- To evaluate the efficacy and impact of continuous subcutaneous insulin infusion (CSII) in children with diabetes mellitus.
- To assess the effect of CSII on daily blood glucose levels and HbA1c in pediatric patients.
Main Methods:
- Six children diagnosed with diabetes mellitus were enrolled in the study.
- Continuous subcutaneous insulin infusion (CSII) therapy was administered to all participants.
- Daily blood glucose monitoring and HbA1c levels were assessed before and during treatment.
Main Results:
- CSII therapy led to near-normalization of daily blood glucose values in the treated children.
- Significant improvements in HbA1c content were observed, indicating better long-term glycemic control.
- The insulin pump used for CSII did not impede the children's normal daily activities.
Conclusions:
- Continuous subcutaneous insulin infusion (CSII) appears to be an effective and well-tolerated treatment modality for children with diabetes mellitus.
- Despite limited experience, CSII shows promise as an improvement over conventional therapies for pediatric diabetes management.
Abstract:
Six diabetic children were treated with continuous subcutaneous insulin infusion (CSII). The daily blood glucose values and the HbA1c-content normalised nearly. The carrying of the pump did not impede any normal activity. Although our experience is still limited, CSII seems to be an improvement in the treatment of children with diabetes mellitus.